Researchers from King's College London and UCB Pharma Inc. recently reported preclinical data on the effects of an anti-mouse neonatal Fc receptor (FcRn) antibody, UCB-4470, on circulating antiphospholipid (aPL) and aPL-induced thrombus formation in mice.
CSPC NBP Pharmaceuticals Co. Ltd. entered an agreement that will grant it exclusive rights to Harbour Biomed Co. Ltd.’s anti-FcRn antibody, batoclimab (HBM-9161), in greater China, including Hong Kong, Macau and Taiwan.
Hanall Biopharma Co. Ltd. has clarified that the new FcRn inhibitor IMVT-1402, unveiled by its licensed partner Immunovant Inc. as a new development program for autoimmune diseases, is a compound discovered and developed by Hanall, HL-161ANS.
Immunovant Inc. has announced a next-generation anti-FcRn, IMVT-1402, for autoimmune diseases. In animal studies, IMVT-1402 has shown deep IgG lowering, similar to the company's lead asset batoclimab, with no or minimal impact on albumin and low-density lipoprotein (LDL).
Harbour Biomed Therapeutics Ltd. said its anti-FcRn monoclonal antibody, batoclimab, generated top-line phase II data in generalized myasthenia gravis, and the company expects to move into a phase III study by the end of this year, with final data reported in April 2022.
